LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Articles
X-vax Technology Inc.
Headquarters:
Jupiter, FL, United States of America
Website:
http://www.x-vax.com
Year Founded:
N/A
Status:
Private
BioCentury
|
Jan 20, 2022
Product Development
Moving beyond a 45-year-old antiviral for herpes
Improved antivirals, antibodies, vaccines and possible cures enter the horizon
Read More
BioCentury
|
Aug 21, 2021
Translation in Brief
Feng Zhang’s SEND mRNA delivery platform; plus in vivo CRISPR screening with MIC-Drop and more
BioCentury’s roundup of translational news
Read More
BioCentury
|
Jul 23, 2021
Management Tracks
Frazier joins General Catalyst as executive chairman of Health Assurance Initiatives
Plus: GSK, Quell, Tectonic, Coherus and more
Read More
BioCentury
|
Oct 3, 2019
Emerging Company Profile
X-Vax: Bucking dogma in HSV vaccine development
Eschewing HSV’s major antigen, X-Vax aims to elicit non-neutralizing antibodies that target infected cells
Read More
BioCentury
|
Jul 25, 2019
Financial News
July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and more
Read More
Items per page:
10
1 - 5 of 5